SCHEMBL30159280

SCHEMBL30159280

CC[C@H](C)[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)C(C)C)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.54
▸ RXFP1 Q9HBX9 8/20 0.50
▸ PTH1R Q03431 3/20 0.49
▸ VIPR1 P32241 1/20 0.49
▸ GLP1R P43220 1/20 0.47
▸ GCGR P47871 1/20 0.47
▸ GIPR P48546 1/20 0.47
▸ TLR2 O60603 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159324 0.97 BACE1 (0.56) BACE1RXFP1PTH1RVIPR1GLP1R
SCHEMBL30159127 0.94 RXFP1 (0.54) BACE1RXFP1PTH1RVIPR1GLP1R
SCHEMBL30159395 0.94 BACE1 (0.51) BACE1RXFP1PTH1RVIPR1GLP1R
SCHEMBL30437160 0.93 BACE1 (0.56) BACE1RXFP1PTH1RVIPR1GLP1R
SCHEMBL30159188 0.91 PTH1R (0.57) BACE1RXFP1PTH1RVIPR1GLP1R
SCHEMBL30159262 0.90 NPY4R (0.48) VIPR1
SCHEMBL31465333 0.89 VIPR1 (0.52) RXFP1PTH1RVIPR1TLR2
SCHEMBL29901564 0.89 BACE1 (0.49) BACE1RXFP1VIPR1GLP1RGCGR
SCHEMBL30906349 0.88 RXFP1 (0.57) RXFP1PTH1RGLP1R
SCHEMBL30599009 0.88 PTH1R (0.55) BACE1RXFP1PTH1RVIPR1GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS LLC (US) 2026-03-12 — — US disclosed
US-12454771-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS LLC (US) 2025-10-28 — — US disclosed
EP-4556467-A2 METHODS FOR ARRAY SYNTHESIS Vibrant Holdings, LLC (US) 2025-05-21 — — EP disclosed
US-12251674-B2 Substrates, systems, and methods for array synthesis and biomolecular analysis VIBRANT HOLDINGS, LLC (US) 2025-03-18 — — US disclosed
EP-3617219-B1 METHODS FOR ARRAY SYNTHESIS VIBRANT HOLDINGS LLC (US) 2025-02-26 — — EP disclosed
US-20230294063-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS, LLC 2023-09-21 — — US disclosed
US-11565231-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS, LLC (US) 2023-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230294063-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, IAPP, GIPR BACE1 791/4885RXFP1 777/4885PTH1R 549/4885
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, CALCB, SPPL2B BACE1 401/4885RXFP1 1521/4885PTH1R 208/4885
US-11565231-B2 Substrates, peptide arrays, and methods VIP, IAPP, GIPR BACE1 791/4885RXFP1 777/4885PTH1R 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback